这是一项随机、开放标签、多中心、全球性第三期研究，旨在确定 durvalumab + tremelimumab 联合治疗对比铂类标准治疗化疗，用于表皮生长因子受体（EGFR）及间变性淋巴瘤激酶（ALK）野生型晚期或转移性 NSCLC 患者第一线治疗的疗效与安全性。

适应症：Non Small Cell Lung Carcinoma NSCLC

入组条件

For inclusion in the study, patients should fulfill the following criteria:
Aged at least 18 years
Documented evidence of Stage IV NSCLC
No activating EGFR mutation or ALK rearrangement
No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC
World Health Organization (WHO) Performance Status of 0 or 1
No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines

Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant
Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment.
Active or prior documented autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

Durvalumab 联合 Tremelimumab 对比标准治疗作为转移性非小细胞肺癌（NSCLC）第一线治疗的研究（NEPTUNE）